To manage myocardial recovery in patients with the HeartWare left ventricular assist device (HVAD), we describe a minimally invasive approach (decommissioning) that involves disconnecting the driveline and occluding the outflow tract through a small left thoracotomy incision, leaving the device in situ, in conjunction with optimal medical therapies and comprehensive assessment of left ventricular recovery. Nine patients (all male, 37 ± 12 years, all nonischemic dilated cardiomyopathy) had an HVAD implanted for 766 ± 343 days. When left ventricular function improved to mild impairment by echocardiography, patients underwent assessment at reduced flow (2578 ± 148 to 1822 ± 67 rpm) with documentation of compensated right heart hemodynamics and ejection fraction 52 ± 8%. Eight of nine patients underwent decommissioning, and 1 patient had a hybrid procedure of percutaneous occlusion of outflow graft and surgical division of driveline. Two patients died postoperatively at 413 days (sepsis) and 810 days (heart failure). In conclusion, in selected patients with nonischemic dilated cardiomyopathy, a prolonged period of HVAD support in conjunction with heart failure medications can lead to recovery of left ventricular function. Surgical decommissioning is then an option to remove these patients from support. These patients are, however, not cured and remain at risk for future deterioration in ventricular function and infections. ASAIO Journal 2017; 63:299-304.
Myocardial recovery in patients on left ventricular assist devices (LVAD) is well documented 1, 2 and, in appropriately selected patients, can be achieved in 24% of implants. 3 This potentially offers patients with a history of end-stage heart failure an alternative to long-term LVAD support with its potential complications or transplantation with its associated risks. Two issues with myocardial recovery on LVADs are clear: 1) that patients with recent-onset nonischemic dilated cardiomyopathy are more likely to recover than those with long-standing nonischemic cardiomyopathy [2] [3] [4] or ischemic patients, and 2) there is a risk of future decline in ventricular function after recovery.
For instance, in a recent report on recovery in the Interagency Registry for Mechanically Assisted Circulatory Support at 1 year post-explantation, 18 out of 21 patients were alive without further intervention, 1 had died, and 2 had undergone transplantation. 3 Thus, it has been proposed that remission rather than recovery is a more appropriate terminology when there is a risk of relapse in the future. 5 In that context, whether a definitive explant operation is needed initially should be questioned. A simpler operation, leaving the device in situ, although occluding the outflow graft and severing the driveline using the device as its own apical plug, will leave a natural orifice to reimplant a new device at a later date should that be needed.
In response to these issues, we have developed a program of myocardial recovery with the HeartWare ventricular assist devices (HVAD) that involves maximally tolerated standard heart failure therapies, monitoring of recovery for prolonged periods (usually well beyond 1 year), careful assessment of recovery at low HVAD flow rates, and then minimally invasive decommissioning surgery, which involves leaving the HVAD in situ, although it occludes the outflow graft and cuts the driveline through a small left thoracotomy incision without the need to arrest the heart. In another patient, a hybrid procedure of percutaneous outflow graft occlusion and surgical division of driveline was performed. We report the first 9 patients who have undergone this program who had devices implanted more than a 7-year period.
Methods
Between July 2009 and Sept 2016, 170 adult patients underwent implantation of the HVAD at the Freeman Hospital as a bridge to transplant. The strategy as indicated in Table 1 was adopted to aid and assess myocardial recovery. In all patients, flow rates of the device were set at time of implantation and set in part to allow some degree of aortic valve opening detectable by echocardiography. Patient details of those that were successfully decommissioned are presented in Table 2 . All patients were male. Eight of the nine patients were on preoperative inotropes, two had intra-aortic balloon pumps, and two patients were on arteriovenous extracorporeal membrane oxygenation. Diagnosis was established by a combination of clinical presentation, family history, and myocardial histology. This study adhered to the terms of the United Kingdom Data and Protection Act and Freedom of Information Act and was approved to obtain confidential information by the local Caldicott Guardian.
Echocardiograms were performed by experienced echocardiographers. Left ventricular dimensions were measured from parasternal long-axis views. As left ventricular function is difficult to quantify in patients with the HeartWare device causing difficulty in obtaining apical windows, a scale of left ventricular function
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HeartWare Left Ventricular Assist Device was used from 1 to 4 (1, normal; 2, mild; 3, moderate; and 4, severe impairment). As this was a semiquantitative measurement, we also obtained computed tomography angiograms for measurement of left ventricular end-diastolic volume and ejection fraction for the final assessment pre-decommissioning at low flow. Right ventricular function with the echocardiograms were also measured using a semiquantitative scale from 1 to 6 (1, normal; 2, mild; 3, mild-moderate; 4, moderate; 5, moderate-severe; and 6, severe). Right heart catheterization for measurement of right and left heart fillings pressures and thermodilution cardiac output was performed, and a cardiopulmonary stress test for determination of peak exercise oxygen consumption was performed.
Surgical Decommissioning
To keep the surgical trauma to the recovered myocardium to a minimum, a new surgical strategy was introduced, 6 not to remove the pump at all, but rather use the pump as a plug. A 5-cm anterolateral thoracotomy was performed via the 6th intercostal space with the patient in the supine position. This small incision allows exposure of the HVAD pump and removal of the three plastic rings covering the outflow graft. The outflow graft was exposed, encircled, and divided. The driveline was than exposed at the lower end of the xiphoid or where it is brought out of the thoracic cavity and divided (Figure 1) . In most cases, it was feasible to pull out the driveline remnant distally at the exit site. In some cases, an additional incision was required to allow removal. In the 9th case, a hybrid procedure was performed with percutaneous closure of the outflow graft and surgical division of the driveline. This was performed because the outflow graft could not be reached through the thoracotomy incision. Anticoagulation with warfarin was continued for an internationalized normalized ratio of 2-2.5 after decommissioning, and antiplatelets were discontinued.
Data Analysis
Data are presented as mean ± standard deviation. Survival curves were composed using SPSS (version 22) and groups compared using the Tarone Ware test. 
Results
nine patients have been surgically decommissioned from this cohort, which represents 5.2% of the total number and 10.0% of those patients with nonischemic dilated cardiomyopathy (mean age 37 ± 12, range 19-53 years; all male). Four other patients in the total cohort who are not included in this report had only partial myocardial recovery but serious complications requiring full ventricular assist device (VAD) explantation: two with prior myocardial infarction (one with recurrent hemorrhage and one with adverse social conditions precluding discharge from hospital), one patient with idiopathic dilated cardiomyopathy and resistant VAD-related pseudomonas sepsis, and another with idiopathic dilated cardiomyopathy and noncompliance-induced device thrombosis. only one of these partially recovered patients was a long-term survivor.
Mean duration of support was 766 ± 343 (range 205-1145) days, and mean follow-up post-decommissioning was 695 ± 341 (range 330-1359) days. The mean hemodynamics of the successful low-flow assessments are presented in Table 3 . The standard anticoagulation regimen was not changed during the low-flow assessments (warfarin target International normalised ratio [InR] 2.7 and aspirin 300 mg daily). on average, there were 1.8 ± 1.0 of these assessments for each patient, repeated until patients had acceptable hemodynamics and left and right ventricular function on low flow. Criteria to proceed with surgical decommissioning were as follows after 5 days of low-flow investigations: unchanged left and right ventricular function by echocardiogram (with at worst mild left and right ventricular function), left ventricular ejection fraction >40% on gated cardiac computed tomography, and pulmonary arterial wedge pressure <15 mm Hg and cardiac index ≥1.8 ml/min/m 2 on low flow. Reasons for not passing the low-flow assessments were as follows: low cardiac output n =1, right ventricular function n =2, left ventricular function n =1, and abnormal pulmonary arterial wedge pressure n =3. of note, all but one patient had recent-onset heart failure. The mean time from the low-flow assessment to the decommissioning procedure was 94 ± 64 days. Mean postoperative length of stay was 6 ± 1 days.
one patient died at 413 days post-decommissioning because of sepsis. This was a patient with poor mobility because of Becker's muscular dystrophy, obesity, and previous methicillin-sensitive staphylococcus aureus colonization of his driveline who had been treated with long-term suppression with flucloxacillin before the decommissioning. The final admission with sepsis was probably precipitated in part by noncompliance with the antibiotic regimen. Another patient died at 810 days post-decommissioning with heart failure. one patient has had a complete VAD explant since the initial decommissioning because of recurrent sepsis. This patient and the remaining six patients are well and free from symptoms of heart failure.
Serial Echocardiograms
Results of serial echocardiograms pre-and post-decommissioning are presented in Figure 2 . on support, over time, there are reductions in left ventricular end-diastolic dimensions and end-systolic dimensions and improvement in left ventricular function grade. of note, it takes approximately 700 days for left ventricular function to improve to the level of mild impairment. Right ventricular function improves to mild to moderately impaired from between moderate and moderate to severe impairment at the time of implant. After decommissioning, there is reduction in left ventricular function again, so that after 1 year post-decommissioning, left ventricular function on average is between mild and moderate dysfunction. In the seven survivors, two have normal left ventricular function, three mild, one moderate, and one severe dysfunction. Left ventricular dimensions do not change, and right ventricular function remains between mild to moderately impaired.
Survival
Survival of the decommissioned cohort from the time of VAD implant was compared with all other HVAD patients implanted at this centre. For the nondecommissioned HVAD cohort, an event included death on the device and death after transplant. Survival was significantly better in the decommissioned group compared with the nondecommissioned patients (Figure 3 ).
Discussion
We demonstrate in this study that carefully selected recovered patients can be safely removed from device support while leaving the HVAD in situ but disconnected. The immediate Figure 1 . Chest X rays of the same patient immediately after ventricular assist device (VAD) implant (left) and then post-surgical decommissioning (right). Arrows point to the driveline. Post-decommissioning, the VAD is in situ, and the arrow indicates the driveline has been cut. The contrast on the images has been increased so that the driveline is more easily seen. 2.3 ± 0.4 Pulmonary arterial oxygen saturation (%) 68 ± 5 Peak exercise oxygen consumption (mL/kg/min) 18.0 ± 4.6 CT ejection fraction (%) 52 ± 8 CT end-diastolic volume (mL) 154 ± 61
CT, computed tomography.
surgical risk is low, but there are potential problems with longterm follow-up with potential sepsis and deteriorating left ventricular function.
Minimally Invasive Surgery to Reduce Risk
Surgery to explant the device can carry significant risk. Birks et al. 7 reported that 3 of 23 HeartMate II patients explanted died perioperatively. Frazier et al. 8 have recently reported a modified technique to explant the HeartMate II device that involves leaving the inflow cannula in place and removing the rest of the device. our technique with the HVAD takes this evolution one step further and retains the device in situ. An alternative is a percutaneous approach using vascular plugs to close the outflow graft, 9 which we have also used in one patient. To date, our approach has not led to any immediate postoperative adverse events, although there are potential long-term problems. All patients have been left on an empiric dose of warfarin anticoagulation to maintain an InR of 2-2.5.
Recovery With the HVAD
The assessment of recovery with the HVAD as described shares a lot of the attributes described with other devices. There is a period of unloading, and when function appears to improve, assessments are performed at low flows. Compared with the study from Birks et al., 7 with the HeartMate II device, the development of recovery with increasing function and reduced dimensions in the current study is significantly slower. In their study, the majority of patients achieved normal ejection fractions by 4-5 months. other groups have shown the same phenomenon. Dandel et al. 10 have shown in a group of patients with a variety of LVADs (although not the HVAD) that the mean duration of support to allow explantation was 4.9 ± 2.8 months. Drakos et al. 12 have likewise shown that the largest increase in ejection fraction on support was at 270 days. The reasons for this are unclear; there are 2 possibilities: 1) that the HVAD has intrinsic less unloading properties than other VADs, and 2) that our setting of aortic valve opening in all patients leads to less unloading. We have previously reported that with the HVAD 13 at 200 days of support, the left ventricular end-diastolic dimension reduces from 7.2 ± 1.0 to 6.9 ± 1.2 cm (at an average of 2522 ± 174 revolutions per minute). In other studies using other continuous flow devices, there is apparently greater unloading. For instance, in a comparison of pulsatile and continuous flow unloading with the HeartMate II device, Kato et al. 14 have shown that after a median of 100 days support, left ventricular end-diastolic dimension reduces from 6.8 ± 1.1 to 5.6 ± 1.5. Likewise, Maybaum et al. 15 have shown greater unloading of the left ventricle in a study involving predominantly the HeartMate II device. However, Gupta et al. 16 with the HVAD have shown at 100 days that left ventricular enddiastolic dimension reduces from 7.1 ± 1.3 to 6.1 ± 1.4 cm, although at a higher mean pump speed of 2693 ± 139 rpm, specifically set so that the aortic valve was closed. Thus, the issue of slow left ventricular remodeling seems to be an issue of the HVAD settings rather than specifically related to the type of device. We do not know whether allowing the aortic valve to open from implantation has benefits in terms of long-term recovery. We do, however, know that an aortic valve that opens is less likely to develop aortic regurgitation and thromboembolic events.
17,18

Long-Term Outcomes
The long-term outcomes of these patients compare favorably to those previously reported with the HeartMate II device. Birks et al. 7 have reported an approximate 50% survival in recovered explanted patients at 750 days, which compares to approximately 50% survival at 2000 days in the current study (Figure 3) . one patient has died of sepsis and one of heart failure. There is potential for future deterioration in left ventricular function, despite the optimal medical treatments and sepsis, and so these patients cannot be considered cured. 5 Dandel et al. have reported a 66% 5-year freedom for heart failure. 10 In a group of 27 explanted patients, Frazier et al. 8 have reported one transplant, one device reimplantation, three strokes, and two deaths for a mean survival time post-explant of 1097 ± 926 days. Leaving the device in situ leaves a natural conduit through which to place a new device should that be needed in the future. An alternative is repair of the apical defect, although we do not know whether this has a beneficial impact on left ventricular function. Ideally, to minimize long-term infection risk, those patients who have had systemic infections while the device is operating should probably have a full explant procedure. our patient who died of sepsis was a high-risk patient for both an explant procedure (obesity with Becker's muscular dystrophy) but also at high risk for infection given the history of colonization with methicillin-sensitive Staphylococcus aureus, and so posed a difficult real-world dilemma.
Conclusions
In selected patients with end-stage heart failure and nonischemic dilated cardiomyopathy supported with the HVAD, a prolonged period of device support in conjunction with optimal heart failure medications can lead to recovery of left ventricular function. Surgical decommissioning is then a practical option to remove these patients from support without the need for extensive surgery. nevertheless, there is a risk of deterioration in left ventricular function and recurrence of heart failure in the long term. 
